Medical guideline

首页肿瘤学指南检索结果

检索结果

按发表年份

共搜索到69条与Recommendation有关的结果

The 2020 Japan Society of Gynecologic Oncology Guidelines for the Treatment of Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

2021年发布于 Journal of Gynecologic Oncology 32卷第2期 所属人体系统：其他 | 腹膜肿瘤

Japan Society of Gynecologic Oncology

The Fifth Edition of the Japan Society of Gynecologic Oncology Guidelines for the Treatment of Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer Was Published in 2020. the Guidelines Contain 6 Chapters-namely (1) Overview of the Guidelines (2) Epithelial Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer (3) Recurrent Epithelial Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer (4) Borderline Epithelial Tumors of the Ovary (5) Malignant Germ Cell Tumors of the Ovary and (6) Malignant Sex Cord-stromal Tumors. Furthermore the Guidelines Comprise 5 Algorithms-namely (1) Initial Treatment for Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer (2) Treatment for Recurrent Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer (3) Initial Treatment for Borderline Epithelial Ovarian Tumor (4) Treatment for Malignant Germ Cell Tumor and (5) Treatment for Sex Cord-stromal Tumor. Major Changes in the New Edition Include the Following: (1) Revision of the Title to "guidelines for the Treatment of Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer" (2) Involvement of Patients and General (male/female) Participants in Addition to Physicians Pharmacists and Nurses (3) Clinical Questions (CQs) in the PICO Format (4) Change in the Expression of Grades of Recommendation and Level of Evidence in Accordance with the GRADE System (5) Introduction of the Idea of a Body of Evidence (6) Categorization of References According to Research Design (7) Performance of Systematic Reviews and Meta-analysis for Three CQs and (8) Voting for Each CQ/recommendation and Description of the Consensus.
指南简介 原文链接
Surgical Management of Oncologic Patient During and after the COVID-19 Outbreak: Practical Recommendations from the Italian Society of Surgical Oncology

2021年发布于 Updates Surg 73卷第1期 所属人体系统：其他 | 治疗方案

Italian Society of Surgical Oncology

COVID-19 Cancer Oncologic Surgery Recommendations
指南简介 原文链接
The 2020 Japan Society of Gynecologic Oncology Guidelines for the Treatment of Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

2021年发布于 Journal of Gynecologic Oncology 32卷第2期 所属人体系统：生殖 | 卵巢肿瘤

Japan Society of Gynecologic Oncology

The Fifth Edition of the Japan Society of Gynecologic Oncology Guidelines for the Treatment of Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer Was Published in 2020. the Guidelines Contain 6 Chapters-namely (1) Overview of the Guidelines (2) Epithelial Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer (3) Recurrent Epithelial Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer (4) Borderline Epithelial Tumors of the Ovary (5) Malignant Germ Cell Tumors of the Ovary and (6) Malignant Sex Cord-stromal Tumors. Furthermore the Guidelines Comprise 5 Algorithms-namely (1) Initial Treatment for Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer (2) Treatment for Recurrent Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer (3) Initial Treatment for Borderline Epithelial Ovarian Tumor (4) Treatment for Malignant Germ Cell Tumor and (5) Treatment for Sex Cord-stromal Tumor. Major Changes in the New Edition Include the Following: (1) Revision of the Title to "guidelines for the Treatment of Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer" (2) Involvement of Patients and General (male/female) Participants in Addition to Physicians Pharmacists and Nurses (3) Clinical Questions (CQs) in the PICO Format (4) Change in the Expression of Grades of Recommendation and Level of Evidence in Accordance with the GRADE System (5) Introduction of the Idea of a Body of Evidence (6) Categorization of References According to Research Design (7) Performance of Systematic Reviews and Meta-analysis for Three CQs and (8) Voting for Each CQ/recommendation and Description of the Consensus.
指南简介 原文链接
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation Or Maintenance Systemic Therapy for Newly Diagnosed Stage Ii, Iii, Or Iv Epithelial Ovary, Fallopian Tube, Or Primary Peritoneal Carcinoma

2021年发布于 Current Oncology 28卷第2期 所属人体系统：生殖 | 卵巢肿瘤

Ontario Health (Cancer Care Ontario)

Objective: to Provide Recommendations on Systemic Therapy Options in Consolidation Or Maintenance Therapy for Women with Newly Diagnosed Stage II III Or IV Epithelial Ovary Fallopian Tube Or Primary Peritoneal Carcinoma Including All Histological Types. Methods: Consistent with the Program in Evidence-based Program's Standardized Approach MEDLINE EMBASE PubMed Cochrane Library and PROSPERO (the International Prospective Register of Systematic Reviews) Databases and Four Relevant Conferences Were Systematically Searched. the Working Group Drafted Recommendations and Revised Them Based on the Comments from Internal and External Reviewers. Results: We Have One Recommendation for Consolidation Therapy and Eight Recommendations for Maintenance Therapy. Overall Consolidation Therapy with Chemotherapy Should Not Be Recommended in the Target Population. for Maintenance Therapy We Recommended Olaparib (Recommendation) Niraparib (Weak Recommendation) Veliparib (Weak Recommendation) and Bevacizumab (Weak Recommendation) for Certain Patients with Newly Diagnosed Stage III-IV Epithelial Ovarian Fallopian Tube Or Primary Peritoneal Carcinoma Respectively. We Do Not Recommend Some Agents as Maintenance Therapy in Four Recommendations. We Are Unable to Specify the Patient Population by Histological Types for Different Maintenance Therapy Recommendations. When New Evidence That Can Impact the Recommendations Is Available the Recommendations Will Be Updated as Soon as Possible.
指南简介 原文链接
Recommendations on the Pathological Report of Pituitary Tumors. a Consensus of Experts of the Spanish Society of Endocrinology and Nutrition and the Spanish Society of Pathology

2021年发布于 Endocrinologia Diabetes Y Nutricion 68卷第3期 所属人体系统：内分泌 | 垂体肿瘤

Spanish Society of Endocrinology and Nutrition Spanish Society of Pathology

Anatomía Patológica Expert Recommendations Immunohistochemistry Inmunohistoquímica Neuroendocrine Tumors Pathology Recomendaciones De Expertos Tumores Neuroendocrinos
指南简介 原文链接
The 2020 Japan Society of Gynecologic Oncology Guidelines for the Treatment of Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

2021年发布于 Journal of Gynecologic Oncology 32卷第2期 所属人体系统：生殖 | 输卵管癌

Japan Society of Gynecologic Oncology

The Fifth Edition of the Japan Society of Gynecologic Oncology Guidelines for the Treatment of Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer Was Published in 2020. the Guidelines Contain 6 Chapters-namely (1) Overview of the Guidelines (2) Epithelial Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer (3) Recurrent Epithelial Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer (4) Borderline Epithelial Tumors of the Ovary (5) Malignant Germ Cell Tumors of the Ovary and (6) Malignant Sex Cord-stromal Tumors. Furthermore the Guidelines Comprise 5 Algorithms-namely (1) Initial Treatment for Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer (2) Treatment for Recurrent Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer (3) Initial Treatment for Borderline Epithelial Ovarian Tumor (4) Treatment for Malignant Germ Cell Tumor and (5) Treatment for Sex Cord-stromal Tumor. Major Changes in the New Edition Include the Following: (1) Revision of the Title to "guidelines for the Treatment of Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer" (2) Involvement of Patients and General (male/female) Participants in Addition to Physicians Pharmacists and Nurses (3) Clinical Questions (CQs) in the PICO Format (4) Change in the Expression of Grades of Recommendation and Level of Evidence in Accordance with the GRADE System (5) Introduction of the Idea of a Body of Evidence (6) Categorization of References According to Research Design (7) Performance of Systematic Reviews and Meta-analysis for Three CQs and (8) Voting for Each CQ/recommendation and Description of the Consensus.
指南简介 原文链接
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation Or Maintenance Systemic Therapy for Newly Diagnosed Stage Ii, Iii, Or Iv Epithelial Ovary, Fallopian Tube, Or Primary Peritoneal Carcinoma

2021年发布于 Current Oncology 28卷第2期 所属人体系统：生殖 | 输卵管癌

Ontario Health (Cancer Care Ontario)

Objective: to Provide Recommendations on Systemic Therapy Options in Consolidation Or Maintenance Therapy for Women with Newly Diagnosed Stage II III Or IV Epithelial Ovary Fallopian Tube Or Primary Peritoneal Carcinoma Including All Histological Types. Methods: Consistent with the Program in Evidence-based Program's Standardized Approach MEDLINE EMBASE PubMed Cochrane Library and PROSPERO (the International Prospective Register of Systematic Reviews) Databases and Four Relevant Conferences Were Systematically Searched. the Working Group Drafted Recommendations and Revised Them Based on the Comments from Internal and External Reviewers. Results: We Have One Recommendation for Consolidation Therapy and Eight Recommendations for Maintenance Therapy. Overall Consolidation Therapy with Chemotherapy Should Not Be Recommended in the Target Population. for Maintenance Therapy We Recommended Olaparib (Recommendation) Niraparib (Weak Recommendation) Veliparib (Weak Recommendation) and Bevacizumab (Weak Recommendation) for Certain Patients with Newly Diagnosed Stage III-IV Epithelial Ovarian Fallopian Tube Or Primary Peritoneal Carcinoma Respectively. We Do Not Recommend Some Agents as Maintenance Therapy in Four Recommendations. We Are Unable to Specify the Patient Population by Histological Types for Different Maintenance Therapy Recommendations. When New Evidence That Can Impact the Recommendations Is Available the Recommendations Will Be Updated as Soon as Possible.
指南简介 原文链接
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation Or Maintenance Systemic Therapy for Newly Diagnosed Stage Ii, Iii, Or Iv Epithelial Ovary, Fallopian Tube, Or Primary Peritoneal Carcinoma

2021年发布于 Current Oncology 28卷第2期 所属人体系统：其他 | 腹膜肿瘤

Ontario Health (Cancer Care Ontario)

Objective: to Provide Recommendations on Systemic Therapy Options in Consolidation Or Maintenance Therapy for Women with Newly Diagnosed Stage II III Or IV Epithelial Ovary Fallopian Tube Or Primary Peritoneal Carcinoma Including All Histological Types. Methods: Consistent with the Program in Evidence-based Program's Standardized Approach MEDLINE EMBASE PubMed Cochrane Library and PROSPERO (the International Prospective Register of Systematic Reviews) Databases and Four Relevant Conferences Were Systematically Searched. the Working Group Drafted Recommendations and Revised Them Based on the Comments from Internal and External Reviewers. Results: We Have One Recommendation for Consolidation Therapy and Eight Recommendations for Maintenance Therapy. Overall Consolidation Therapy with Chemotherapy Should Not Be Recommended in the Target Population. for Maintenance Therapy We Recommended Olaparib (Recommendation) Niraparib (Weak Recommendation) Veliparib (Weak Recommendation) and Bevacizumab (Weak Recommendation) for Certain Patients with Newly Diagnosed Stage III-IV Epithelial Ovarian Fallopian Tube Or Primary Peritoneal Carcinoma Respectively. We Do Not Recommend Some Agents as Maintenance Therapy in Four Recommendations. We Are Unable to Specify the Patient Population by Histological Types for Different Maintenance Therapy Recommendations. When New Evidence That Can Impact the Recommendations Is Available the Recommendations Will Be Updated as Soon as Possible.
指南简介 原文链接
Taiwan Nutritional Consensus on the Nutrition Management for Gastric Cancer Patients Receiving Gastrectomy

2021年发布于 Journal of the Formosan Medical Association 120卷第(1 Pt 1)期 所属人体系统：消化 | 胃癌

Gastroenterological Society of Taiwan

Gastrectomy Guidelines National Recommendations Nutritional Support
指南简介 原文链接
Recommendations on Management of Gynecological Malignancies During the COVID-19 Pandemic: Perspectives from Chinese Gynecological Oncologists

2020年发布于 J Gynecol Oncol 31卷第4期 所属人体系统：生殖 | 妇科肿瘤

无

COVID-19 Gynecological Malignancies Management Pandemic Recommendations.
指南简介 原文链接
Management of Patients with High-risk and Advanced Prostate Cancer in the Middle East: Resource-stratified Consensus Recommendations

2020年发布于 World journal of urology 38卷第3期 所属人体系统：生殖 | 前列腺肿瘤

A Consortium of Urologists Medical Oncologists Radiation Oncologist and Imaging Specialists Practicing in Lebanon Syria Iraq Kuwait and Saudi Arabia

Consensus Middle East Multidisciplinary Prostate Cancer Resource-stratified Recommendations.
指南简介 原文链接
ESUR/ESUI Consensus Statements on Multi-parametric MRI for the Detection of Clinically Significant Prostate Cancer: Quality Requirements for Image Acquisition, Interpretation and Radiologists' Training

2020年发布于 European Radiology 30卷第10期 所属人体系统：生殖 | 前列腺肿瘤

European Society of Urogenital Radiology EAU Section of Urologic Imaging

Multi-parametric MRI in the Diagnostic Pathway of Prostate Cancer Has a Well-established Upfront Role in the Recently Updated European Association of Urology Guideline and American Urological Association Recommendations. • Suboptimal Image Acquisition and Reporting at an Individual Level Will Result in Clinicians Losing Confidence in the Technique and Returning to the (non-MRI) Systematic Biopsy Pathway. Therefore It Is Crucial to Establish Quality Criteria for the Acquisition and Reporting of MpMRI. • to Ensure High-quality Prostate MRI Experts Consider Checking and Reporting of Image Quality Mandatory. Prostate Radiologists Must Attend Theoretical and Hands-on Courses Followed by Supervised Education and Must Perform Regular Self- and External Performance Assessments.
指南简介 原文链接
Recommendations for Surveillance and Follow-up of Men with Testicular Germ Cell Tumors: a Multidisciplinary Consensus Conference by the Italian Germ Cell Cancer Group and the Associazione Italiana Di Oncologia Medica

2020年发布于 Critical Reviews in Oncology Hematology 137卷第期 所属人体系统：生殖 | 睾丸肿瘤

Italian Germ Cell Cancer Group and the Associazione Italiana Di Oncologia Medica

Consensus Follow-up Germ Cell Tumor Nonseminoma Recommendation Risk Factor Seminoma Surveillance.
指南简介 原文链接
Advanced Renal Cell Carcinoma (RCC) Management: an Expert Panel Recommendation from the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG)

2020年发布于 J Cancer Res Clin Oncol 146卷第7期 所属人体系统：泌尿 | 肾癌

Latin American Cooperative Oncology Group Latin American Renal Cancer Group

Cytoreductive Nephrectomy Immunotherapy Recommendations Renal Cell Carcinoma Treatment.
指南简介 原文链接
Special Considerations in the Management of Adult Patients with Acute Leukaemias and Myeloid Neoplasms in the COVID-19 Era: Recommendations from a Panel of International Experts

2020年发布于 Lancet Haematol 7卷第8期 所属人体系统：循环 | 骨髓瘤

无

Acute Leukaemias Myeloid Neoplasms Management COVID-19 Recommendations
指南简介 原文链接
How to Capture Cytogenetic and Molecular Abnormalities Into ProMISe Database for Hematological Malignancies: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)

2020年发布于 Bull Cancer 107卷第1S期 所属人体系统：循环 | 血液肿瘤

Francophone Society of Bone Marrow Transplantation and Cellular Therapy

Biologie Moléculaire Cytogenetics Cytogénétique Entering ProMISe Molecular Biology Recommandations SFGM-TC SFGM-TC Recommendations Saisie Sur ProMISe.
指南简介 原文链接
ESMO Management and Treatment Adapted Recommendations in the COVID-19 Era: Breast Cancer

2020年发布于 ESMO Open 5卷第Suppl 3期 所属人体系统：生殖 | 乳腺肿瘤

European Society for Medical Oncology

COVID-19 ESMO Adapted Recommendations Breast Cancer.
指南简介 原文链接
GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID-19 Pandemic in Spain

2020年发布于 Oncologist 25卷第9期 所属人体系统：生殖 | 乳腺肿瘤

 GEICAM Spanish Breast Cancer Group

Breast Cancer COVID-19 Expert Recommendations Pandemic SARS-CoV-2.
指南简介 原文链接
Breast Imaging and Cancer Diagnosis During the COVID-19 Pandemic: Recommendations from the Italian College of Breast Radiologists by SIRM

2020年发布于 Radiol Med 125卷第10期 所属人体系统：生殖 | 乳腺肿瘤

Italian Society of Medical Radiolog

Breast Cancer Breast Care Recommendations COVID-19 Personal Protective Equipment (PPE) Priority Categories.
指南简介 原文链接
Radiation Treatment of Hemato-oncological Patients in Times of the COVID-19 Pandemic : Expert Recommendations from the Radiation Oncology Panels of the German Hodgkin Study Group and the German Lymphoma Alliance

2020年发布于 Strahlenther Onkol 196卷第12期 所属人体系统：循环 | 血液肿瘤

Radiation Oncology Panels of the German Hodgkin Study Group German Lymphoma Alliance

COVID SARS-CoV-2 Hematology Lymphoma Recommendation.
指南简介 原文链接

人体系统

共搜索到69条 与Recommendation有关的结果

2021年 发布于 Journal of Gynecologic Oncology 32卷 第2期 所属人体系统： 其他 | 腹膜肿瘤

Japan Society of Gynecologic Oncology

2021年 发布于 Updates Surg 73卷 第1期 所属人体系统： 其他 | 治疗方案

Italian Society of Surgical Oncology

2021年 发布于 Journal of Gynecologic Oncology 32卷 第2期 所属人体系统： 生殖 | 卵巢肿瘤

Japan Society of Gynecologic Oncology

2021年 发布于 Current Oncology 28卷 第2期 所属人体系统： 生殖 | 卵巢肿瘤

Ontario Health (Cancer Care Ontario)

2021年 发布于 Endocrinologia Diabetes Y Nutricion 68卷 第3期 所属人体系统： 内分泌 | 垂体肿瘤

Spanish Society of Endocrinology and Nutrition Spanish Society of Pathology

2021年 发布于 Journal of Gynecologic Oncology 32卷 第2期 所属人体系统： 生殖 | 输卵管癌

Japan Society of Gynecologic Oncology

2021年 发布于 Current Oncology 28卷 第2期 所属人体系统： 生殖 | 输卵管癌

Ontario Health (Cancer Care Ontario)

2021年 发布于 Current Oncology 28卷 第2期 所属人体系统： 其他 | 腹膜肿瘤

Ontario Health (Cancer Care Ontario)

2021年 发布于 Journal of the Formosan Medical Association 120卷 第(1 Pt 1)期 所属人体系统： 消化 | 胃癌

Gastroenterological Society of Taiwan

2020年 发布于 J Gynecol Oncol 31卷 第4期 所属人体系统： 生殖 | 妇科肿瘤

无

2020年 发布于 World journal of urology 38卷 第3期 所属人体系统： 生殖 | 前列腺肿瘤

A Consortium of Urologists Medical Oncologists Radiation Oncologist and Imaging Specialists Practicing in Lebanon Syria Iraq Kuwait and Saudi Arabia

2020年 发布于 European Radiology 30卷 第10期 所属人体系统： 生殖 | 前列腺肿瘤

European Society of Urogenital Radiology EAU Section of Urologic Imaging

2020年 发布于 Critical Reviews in Oncology Hematology 137卷 第期 所属人体系统： 生殖 | 睾丸肿瘤

Italian Germ Cell Cancer Group and the Associazione Italiana Di Oncologia Medica

2020年 发布于 J Cancer Res Clin Oncol 146卷 第7期 所属人体系统： 泌尿 | 肾癌

Latin American Cooperative Oncology Group Latin American Renal Cancer Group

2020年 发布于 Lancet Haematol 7卷 第8期 所属人体系统： 循环 | 骨髓瘤

无

2020年 发布于 Bull Cancer 107卷 第1S期 所属人体系统： 循环 | 血液肿瘤

Francophone Society of Bone Marrow Transplantation and Cellular Therapy

2020年 发布于 ESMO Open 5卷 第Suppl 3期 所属人体系统： 生殖 | 乳腺肿瘤

European Society for Medical Oncology

2020年 发布于 Oncologist 25卷 第9期 所属人体系统： 生殖 | 乳腺肿瘤

 GEICAM Spanish Breast Cancer Group

2020年 发布于 Radiol Med 125卷 第10期 所属人体系统： 生殖 | 乳腺肿瘤

Italian Society of Medical Radiolog

2020年 发布于 Strahlenther Onkol 196卷 第12期 所属人体系统： 循环 | 血液肿瘤

Radiation Oncology Panels of the German Hodgkin Study Group German Lymphoma Alliance

共搜索到69条与Recommendation有关的结果

2021年发布于 Journal of Gynecologic Oncology 32卷第2期 所属人体系统：其他 | 腹膜肿瘤

2021年发布于 Updates Surg 73卷第1期 所属人体系统：其他 | 治疗方案

2021年发布于 Journal of Gynecologic Oncology 32卷第2期 所属人体系统：生殖 | 卵巢肿瘤

2021年发布于 Current Oncology 28卷第2期 所属人体系统：生殖 | 卵巢肿瘤

2021年发布于 Endocrinologia Diabetes Y Nutricion 68卷第3期 所属人体系统：内分泌 | 垂体肿瘤

2021年发布于 Journal of Gynecologic Oncology 32卷第2期 所属人体系统：生殖 | 输卵管癌

2021年发布于 Current Oncology 28卷第2期 所属人体系统：生殖 | 输卵管癌

2021年发布于 Current Oncology 28卷第2期 所属人体系统：其他 | 腹膜肿瘤

2021年发布于 Journal of the Formosan Medical Association 120卷第(1 Pt 1)期 所属人体系统：消化 | 胃癌

2020年发布于 J Gynecol Oncol 31卷第4期 所属人体系统：生殖 | 妇科肿瘤

2020年发布于 World journal of urology 38卷第3期 所属人体系统：生殖 | 前列腺肿瘤

2020年发布于 European Radiology 30卷第10期 所属人体系统：生殖 | 前列腺肿瘤

2020年发布于 Critical Reviews in Oncology Hematology 137卷第期 所属人体系统：生殖 | 睾丸肿瘤

2020年发布于 J Cancer Res Clin Oncol 146卷第7期 所属人体系统：泌尿 | 肾癌

2020年发布于 Lancet Haematol 7卷第8期 所属人体系统：循环 | 骨髓瘤

2020年发布于 Bull Cancer 107卷第1S期 所属人体系统：循环 | 血液肿瘤

2020年发布于 ESMO Open 5卷第Suppl 3期 所属人体系统：生殖 | 乳腺肿瘤

2020年发布于 Oncologist 25卷第9期 所属人体系统：生殖 | 乳腺肿瘤

2020年发布于 Radiol Med 125卷第10期 所属人体系统：生殖 | 乳腺肿瘤

2020年发布于 Strahlenther Onkol 196卷第12期 所属人体系统：循环 | 血液肿瘤